Chemotherapy News and Research

Latest Chemotherapy News and Research

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced the initiation of a Phase I/IIa dose escalation study of patients suffering from idiopathic CD4 lymphocytopenia (ICL).

15 Oct 2009

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Analysis of a small number of marker genes may determine in a matter of hours if a patient with gastrointestinal stromal tumors (GIST) would respond to a targeted molecular drug regimen. This analysis could allow clinicians to determine if they have chosen the best course of action or need to consider another alternative.

15 Oct 2009

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

A genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure, according to a new study reported at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Online medical journal to be launched

Two Johns Hopkins Children's Center researchers have assembled a 25-member editorial board of international experts to launch a quarterly online medical journal devoted to original research and commentary on the use of computer automation in the day-to-day practice of medicine.

15 Oct 2009

Institute of Medicine elects two new members from St. Jude Children's Research Hospital

Michael Kastan, M.D., Ph.D., and Mary Relling, Pharm.D., of St. Jude Children's Research Hospital, have been elected to the Institute of Medicine (IOM), a prestigious branch of the National Academy of Sciences.

15 Oct 2009

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Research scientists from Massachusetts General Hospital, Boston, have developed a novel bioengineered treatment that has shown promise in targeting pancreatic cancer without causing damage to healthy noncancer cells, a typical problem of chemotherapy.

14 Oct 2009

Breakthrough in pancreatic cancer treatment

Epeius Biotechnologies (www.epeiusbiotech.com) confirms the first real breakthrough for pancreatic cancer seen in years; publishes a landmark report of tumor-targeted Rexin-G as stand-alone therapy in chemotherapy-resistant pancreatic cancer.

14 Oct 2009

Researchers develop magneto-nano sensor chip to detect cancer

Searching for biomarkers that can warn of diseases such as cancer while they are still in their earliest stage is likely to become far easier thanks to an innovative biosensor chip developed by Stanford University researchers.

14 Oct 2009

SCID infants who receive early bone marrow transplants are likely to have fewer complications

Mention the words "bubble boy" and many will recall David Vetter, the kid with big eyes and a thick thatch of dark hair who died 25 years ago after spending almost the entire 12 years of his life in a germ-free, plastic bubble. David was born with severe combined immune deficiency, or SCID, a condition that robbed him of an immune system.

14 Oct 2009

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

OPKO Health, Inc. today announced that it has entered into a definitive agreement with Schering-Plough Corporation to acquire assets relating to Schering’s neurokinin-1 (NK-1) receptor antagonist program. Rolapitant, the lead product, recently completed Phase II clinical testing for prevention of nausea and vomiting related to cancer chemotherapy and surgery, and other indications.

14 Oct 2009

Older generation antibiotic for treating colon cancer

A new Tel Aviv University drug, based on an older generation antibiotic, may provide doctors with an effective and innovative method of treating colon cancer in both its incipient and full-blown stages ― and minimize the need for painful, uncomfortable colonoscopies and surgical polyp removal.

14 Oct 2009

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Epeius Biotechnologies Corporation today announced more stunning results of its pioneering clinical studies of Rexin-G, the world's first and, so far only, tumor-targeted genetic medicine to be validated in the clinic.

14 Oct 2009

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

An anticancer drug that is commonly used to treat lung and colon malignancies is having a benefit and potentially prolonging survival in patients with invasive bladder cancer, researchers reported at the 2009 Clinical Congress of the American College of Surgeons.

14 Oct 2009

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

At the moment, doctors rely on biopsy analysis to determine the progression of eye cancer. However, researchers now believe that a new technology, bioluminescence imaging (BLI), will allow doctors to detect tumors earlier and quickly choose a method of treatment that doesn't necessarily involve eye surgery.

14 Oct 2009

Statistical model helps identify patients who need to undergo further cancer treatment

A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy. The analysis, to be published in the December 1, 2009 issue of CANCER, a peer-reviewed journal of the American Cancer Society, concludes that the model, which considers both how far the cancer has spread and other information, such as how the cancer cells look under the microscope and the time between diagnosis and surgery, could better identify patients who need to undergo further treatment.

13 Oct 2009

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that additional results from its Phase 3 trial (SYMMETRYSM) of elesclomol in combination with paclitaxel in metastatic melanoma was presented at the Perspectives in Melanoma XIII Conference by Steven O’Day, M.D., principal investigator and Chief of Research and Director of the Melanoma Program at the Angeles Clinic in Santa Monica, California.

12 Oct 2009

Study on Lumalier's automated UV device for decontaminating hospital rooms presented at the ICAAC

In a study presented at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), researchers used a mobile, automated UV device to decontaminate hospital rooms at the Cleveland Veterans Affairs (VA) Medical Center in Ohio and analyzed its ability to remove troublesome bacteria, including C. difficile spores.

12 Oct 2009

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

Celator Pharmaceuticals today announced that it has completed enrollment in its Phase 2 multicenter, randomized, open-label clinical trial of CPX-351 (Cytarabine:Daunorubicin) Liposome Injection versus conventional cytarabine and daunorubicin therapy ("7+3") in patients 60-75 years of age with untreated acute myeloid leukemia (AML).

12 Oct 2009

First evidence that personalized medicine leads to better outcomes

A statistical model can accurately predict which patients will have poor outcomes after bladder surgery and can determine the need for chemotherapy.

12 Oct 2009

Breast cancer patients who achieve pathological complete response have better outcomes

Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.

12 Oct 2009

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cytheris initiates Phase I/IIa dose escalation study of patients suffering from ICL

Marker genes help determine the effectiveness of targeted molecular drug regimen for treating GIST

Genetic mutation implicated in breast and ovarian cancers could also have a role in causing heart failure: Study

Online medical journal to be launched

Institute of Medicine elects two new members from St. Jude Children's Research Hospital

Research scientists develop bioengineered treatment for targeting pancreatic cancer

Breakthrough in pancreatic cancer treatment

Researchers develop magneto-nano sensor chip to detect cancer

SCID infants who receive early bone marrow transplants are likely to have fewer complications

OPKO Health signs agreement with Schering-Plough to acquire assets relating to NK-1 program

Older generation antibiotic for treating colon cancer

Epeius Biotechnologies announces clinical study results of tumor-targeted genetic medicine

Bladder cancer patients benefit from anticancer drug that is used to treat lung and colon malignancies: Study

Bioluminescence imaging distinguishes tumor growth in vivo; leads to early treatment of eye cancer

Statistical model helps identify patients who need to undergo further cancer treatment

Synta Pharmaceuticals updates its Phase 3 SYMMETRY trial results at the Melanoma XIII Conference

Study on Lumalier's automated UV device for decontaminating hospital rooms presented at the ICAAC

Celator Pharmaceuticals enrolls 120 patients in CPX-351 Phase 2 study

First evidence that personalized medicine leads to better outcomes

Breast cancer patients who achieve pathological complete response have better outcomes

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Chemotherapy News and Research

Latest Chemotherapy News and Research

Cancer Research eBook

Discover how SciY empowers scientists

Why use light scattering to analyze proteins and viral vectors?

Changing the landscape of R&D to build clinical success from the ground up

Newsletters you may be interested in